Gene Sequencing Has The Bulls Talking And The Numbers Will Turn Bears

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Contributor Since 2015

If you have any questions about my research or any data related to my blogs, just inquire about them via comment. I am a 24 year old University of Pittsburgh Alumni with a BSBA in Finance, Minor in Economics, and FMVA from the Corporate Finance Institute. I also have several certificates from Ivy League Universities such as, Yale, Columbia, and Penn. From Penn, I studied Corporate Finance and Accounting. From Yale, I studied Financial Markets with Robert Shiller and the Global Financial Crisis with Timothy Geithner. I am also a holder of the Bloomberg Market Concepts (BMC) Education Certificate.

Today, I build database models in R & algorithmic trading models in Python. My specialties include portfolio creation and optimization, as well as, portfolio stress testing.

From a purely strategic perspective, I have been studying the pharmaceutical industry for over 8 years. Particularly, I have invested in the top performing biopharmaceutical industry and continue to do so via buy & hold strategy. I am also interested in investments related to the biotechnology and life science sectors, but may speak to the economy as a whole in some articles as well. Otherwise, I am an equity options trader known for predicting a 1987 like market crash before the 2020 election in late September of 2019 (read below). I am also known for long-term calling volatility indexes in late February before the March 2020 stock market rout.


  • Cost of Gene Sequencing is expected to decrease dramatically over the next decade.
  • The Human Genome Project has sparked an information revolution, and is all but finished.
  • Equipment manufacturing leaders will need to consolidate to harvest more profits in the future.

A quick round of applause to the analysts with buy ratings and calls on [[PACB]]. After a 300% rally, Bio-rad (BIO) and Illumina (ILMN) had to be feeling the competitive pressure here and decided to collaborate on a next-generation sequencer for single cell analysis. These sequencers are expensive, so when research institutions buy them, they want to know its the fastest it can be and will save them money compared to current process. Alternate traditional methods in sequencing usually include some sort of assay-based model. A lot of the time this an expensive outsourcing operation. However, thanks to the introduction of PCR machines and on-chip sequencing, thousands of cells can be analyzed in hours.

NVS Chart

NVS data by YCharts

One of the manufacturers of such systems that trades at ridiculously low valuation when compared to the rest of the industry players is WaferGen Biosystems (WGBS). The reason I can say that it has a cheap relative valuation, is because of their Price/Sales ration and a conflicting high demand for their systems in the surrounding market environment (Pharmaceutical Discovery/Development). For example, Juno Therapeutics (JUNO) bought a private company, AbVitro, whose single cell sequencing technology cost them $78M in cash and 1.289M shares of Juno, which were above $40/shr at the time of the acquisition. So Juno paid well over $100M to acquire single cell sequencing tech, adding more evidence that WaferGen should have a higher valuation just based-off of acquisition premiums paid in the market. 


Technicals on this Nasdaq titan, have it running to book value at about 50 cents a share. An overlooked penny stock to say the least. WaferGen is tiny and barely has a slice of the market share, however with strong European exposure and the Luxembourg Institute of Health (LIH) introducing their systems to new drug developers, I expect system their sales to spread rapidly.

The ICell8 was developed with the Karolinska institute in Sweden and has already attracted buyers like Genentech, University of Texas MD Anderson Cancer Center, and the Broad Institute of MIT and Harvard. With a full suite of options, WaferGen is bound to either get acquired for their wonderful tax incentives in the Netherlands, or become the cheapest option for researchers and outsourcing solutions in Europe. After a wave of IPOs last year, large companies are just now pursuing drug discovery options in Europe, and researchers with big budgets are hungry for tools to gather information.

BIO Chart

BIO data by YCharts

So, how much did research institutions and drug developers pay for gene sequencing last year? A little over $2B and that's expected to grow 10 fold to $20B by 2020. Expectations for 2016 are over $6.5B and the expected CAGR after 2016 is 17.5%. Welcome to the big leagues Gene Sequencing.

With Cap-ex and investment in R&D sky-high, the only thing that can stop a rally in the industry would be huge losses in pharmaceutical and biologic sales. But both have pharmaceutical sales and biologic sales have been crushing expectations, so I would expect this trend to continue going forward.

Disclosure: I am/we are long WGBS, ILMN, BIO, PACB.

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.